Wedbush analyst Laura Chico maintained a Buy rating on Viridian Therapeutics today and set a price target of $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Laura Chico’s rating is based on the recent comparative analysis between Viridian Therapeutics’ veligrotug and Roche’s Satralizumab in treating Thyroid Eye Disease (TED). The data from Roche’s Phase 3 studies showed that Satralizumab had a lower placebo-adjusted proptosis response compared to veligrotug, which demonstrated a significantly higher efficacy in the THRIVE-1 study. Additionally, veligrotug showed a faster time to establish proptosis benefit, reinforcing the potential of IGF-1R as a therapeutic target in TED.
These findings suggest that veligrotug has a competitive edge over Satralizumab, especially as Viridian approaches its Biologics License Application (BLA) submission. The removal of a competitive threat and the validation of veligrotug’s efficacy support the positive outlook for Viridian Therapeutics. Consequently, Laura Chico maintains a Buy rating for VRDN, anticipating favorable developments for the company into 2026.